Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Oncternal Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.oncternal.com
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: James B. Breitmeyer, MD, PhD
Number Of Employees: 27
Enterprise Value: $-2,408,440
PE Ratio: -0.05
Exchange/Ticker 1: NASDAQ:ONCT
Exchange/Ticker 2: N/A
Latest Market Cap: $1,558,600
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Dec 7, 2023
Discovery & Translation
Zhang team discovers new CRISPR-Cas systems; plus E3 ligase targets and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 21, 2023
Management Tracks
Kaufmann joins Kyowa Kirin
Plus: Tan joins Heritas and updates from Noema and Versameb
BioCentury | Sep 11, 2021
Management Tracks
New CEO for Eden following conviction of JHL execs
Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more
BioCentury | Sep 3, 2021
Management Tracks
Civetta picks Roberts as CEO
Plus, management moves at Crinetics, OraSure, Silence, Avacta, Oncternal and more
BioCentury | Jul 9, 2021
Management Tracks
Borio joins CEPI as SAB member; plus Aeglea, Codiak, Nordic Nanovector, BioShin and more
Luciana Borio, the senior fellow for global health at the Council on Foreign Relations, became a member of the scientific advisory board at Coalition for Epidemic Preparedness Innovations (CEPI).
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Apr 14, 2021
Management Tracks
CEO succession at Amarin; plus Lilly, IGM, Jounce and more
John Thero will retire as president, CEO and board member at Amarin Corp. plc (NASDAQ:AMRN) on August 1. Thero will be replaced by Karim Mikhail, SVP and head of commercial for Europe at the
BioCentury | Mar 18, 2021
Management Tracks
Clyburn takes helm as president of Merck’s human health franchise; plus Iovance, Harmony, Shattuck and more
Michael Nally is stepping down as chief marketing officer of human health at Merck & Co. (NYSE:MRK). Frank Clyburn, Merck’s chief commercial officer, human health, will become president of
BioCentury | Dec 8, 2020
Product Development
ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal
ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and
Items per page:
1 - 10 of 17